---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-005455"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T13:18:56.511881+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma completes Phase 1 studies for single-dose bird flu drug tivoxavir marboxil

## Summary
- Phase 1 trial showed safety, tolerability, and PK supporting dosing for H5N1 treatment and prevention.
- No significant treatment-related adverse events reported across four dose levels in healthy volunteers.
- Preclinical data showed potent inhibition of drug-resistant and highly pathogenic bird flu viruses.
- Company plans to use data to guide upcoming regulatory meetings for accelerated development.

## SEC filing metadata
- accession: 0001104659-25-005455
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/0001104659-25-005455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/tm253126d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-005455
- JSON: https://secwatch.observer/filing/0001104659-25-005455.json
- Plain text: https://secwatch.observer/filing/0001104659-25-005455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.